ClinicalTrials.gg
CompletedNCT02014129Updated Aug 24, 2020Results posted

A Study of LY2835219 in Japanese Participants With Advanced Cancer

A Phase 1 interventional study of LY2835219 in Neoplasm Metastasis and Lymphoma, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-08-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing abemaciclib in Neoplasm Metastasis — 3 open to participants now, 8 under way, 3 of them phase 3. abemaciclib · Neoplasm Metastasis.

Enrollment
15th of 15
12 · median 48
Started
2013
the only one that year
Phase 1
5 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
9 of 15
Eli Lilly and Company

Among the 15 studies testing abemaciclib in Neoplasm Metastasis, this one is the 15th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 1, and was the 1st registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

3 of the 15 studies testing abemaciclib in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing abemaciclib in Neoplasm Metastasis, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.

03

Conditions studied

  • Neoplasm Metastasis
  • Lymphoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological or cytological evidence of a diagnosis of cancer (either a solid tumor or a lymphoma) that is advanced and/or
  • Must be, in the judgment of the investigator, an appropriate candidate for the experimental therapy after available standard therapies have failed to provide clinical benefit for their disease
  • Have the presence of measurable or non- as defined by the Guideline Version 1.1, or the Revised Response Criteria for Malignant Lymphoma Guideline
  • Have adequate organ function
  • Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, immunotherapy, and therapy, for at least 21 days before the first dose of study drug and recovered from the acute effects of any such therapy
  • Males must agree to use medically approved barrier precautions during the study and for 3 months following the last dose of study drug
  • Females with child bearing potential: must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test ≤7 days before the first dose of study drug.
  • A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, the female must stop breastfeeding from the day of the first study drug administration until at least 3 months after the last administration
  • Have an estimated of ≥12 weeks
  • Are able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within 21 days of the initial dose of study drug with an experimental agent for noncancer indications that has not received regulatory approval for any indication
  • Have a medical history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (e.g., ventricular tachycardia and ventricular fibrillation) or sudden cardiac arrest
  • Have a baseline with any of the following findings on screening (ECG): ventricular tachycardia, ventricular fibrillation, abnormal using Bazett's formula (QTcB) (defined as ≥470 milliseconds), or evidence of acute myocardial ischemia
  • Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)
  • Have symptomatic central nervous system (CNS) or . For asymptomatic participants without history of CNS malignancy or metastases
  • Have evidence or history of a leukemia
  • Have received a stem-cell transplant. As an exception, a participant with lymphoma who received an stem-cell transplant is eligible for the study, if more than 75 days have passed before the initial dose of study drug
  • Have active bacterial, fungal, and/or known viral infection (for example, [HIV], , or )
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Cohort 1 - 100 mg Abemaciclib

    100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.

    Drug: LY2835219

  • Experimental
    Cohort 2 - 150 mg Abemaciclib

    150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.

    Drug: LY2835219

  • Experimental
    Cohort 3 - 200 mg Abemaciclib

    200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.

    Drug: LY2835219

Interventions

  • Administered orally

    Also known as: abemaciclib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)

    DLT is defined as an adverse event between Day -3 and Day 29 of Cycle 1 that is possibly related to the study drug and fulfills any one of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.

    Time frame: Cycle 1 = 32 days

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Abemaciclib

    Maximum plasma concentration on Day -3 and Day 28 of Cycle 1.

    Time frame: Cycle 1 Day -3: Predose, 1, 2, 4, 6, 8, 10, 24, 48 and 72 hours (hr) postdose; Cycle 1 Day 28: Predose, 1, 2, 4, 6, 8, 10 and 24 hr postdose (Cycle 1 = 32 days)

  2. Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of Abemaciclib

    AUC on Day -3 and Day 28 of Cycle 1 are AUC from time zero to infinity \[AUC(0-∞)\] and AUC during one dosing interval at steady state (AUCτ,ss), respectively.

    Time frame: Cycle 1 Day -3: Predose, 1, 2, 4, 6, 8, 10, 24, 48 and 72 hr postdose; Cycle 1 Day 28: Predose, 1, 2, 4, 6, 8, 10 and 24 hr postdose (Cycle 1 = 32 days)

  3. Percentage of Participants With a Tumor Response: Objective Response Rate (ORR)

    Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

    Time frame: Baseline to Measured Progressive Disease (Up To 24 months)

07

Results

Posted Aug 24, 2020

Participant flow

Participants completed the trial if they received at least one dose of study drug and met discontinuation criteria.

Participant flow — Overall Study
MilestoneCohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg Abemaciclib
Started336
Received at least one dose of study drug336
Completed336
Not completed000

Outcome measures

PrimaryNumber of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)

DLT is defined as an adverse event between Day -3 and Day 29 of Cycle 1 that is possibly related to the study drug and fulfills any one of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.

Time frame:
Cycle 1 = 32 days
Reported as:
Count of participants · Participants
Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)
ParticipantsCohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg Abemaciclib
Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)001
SecondaryPharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Abemaciclib

Maximum plasma concentration on Day -3 and Day 28 of Cycle 1.

Time frame:
Cycle 1 Day -3: Predose, 1, 2, 4, 6, 8, 10, 24, 48 and 72 hours (hr) postdose; Cycle 1 Day 28: Predose, 1, 2, 4, 6, 8, 10 and 24 hr postdose (Cycle 1 = 32 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Abemaciclib
nanogram per milliliter (ng/mL)Cohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg Abemaciclib
Cycle 1 Day -3127 ± 51167 ± 40214 ± 87
Cycle 1 Day 28NA ± NANA ± NA298 ± 64
SecondaryPharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of Abemaciclib

AUC on Day -3 and Day 28 of Cycle 1 are AUC from time zero to infinity \[AUC(0-∞)\] and AUC during one dosing interval at steady state (AUCτ,ss), respectively.

Time frame:
Cycle 1 Day -3: Predose, 1, 2, 4, 6, 8, 10, 24, 48 and 72 hr postdose; Cycle 1 Day 28: Predose, 1, 2, 4, 6, 8, 10 and 24 hr postdose (Cycle 1 = 32 days)
Reported as:
Geometric mean · Nanogram*hour/Millilitre (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of Abemaciclib
Nanogram*hour/Millilitre (ng*hr/mL)Cohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg Abemaciclib
AUC(0-∞)NA ± NA4450 ± 395480 ± 95
AUCτ,ss (n=2,2,5)NA ± NANA ± NA3020 ± 73
SecondaryPercentage of Participants With a Tumor Response: Objective Response Rate (ORR)

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

Time frame:
Baseline to Measured Progressive Disease (Up To 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Tumor Response: Objective Response Rate (ORR)
percentage of participantsCohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg Abemaciclib
Percentage of Participants With a Tumor Response: Objective Response Rate (ORR)000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - 100 mg Abemaciclib—0/3 (0%)3/3 (100%)
Cohort 2 - 150 mg Abemaciclib—2/3 (66.7%)3/3 (100%)
Cohort 3 - 200 mg Abemaciclib—2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg Abemaciclib
Gastric fistulaGastrointestinal disorders0/31/30/6
Biliary tract infectionInfections and infestations0/31/30/6
Lung infectionInfections and infestations0/31/30/6
Decreased appetiteMetabolism and nutrition disorders0/30/31/6
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/31/6
Deep vein thrombosisVascular disorders0/30/31/6
Most frequent other events
Showing 10 of 65
Most frequent other events
EventCohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg Abemaciclib
DiarrhoeaGastrointestinal disorders1/32/36/6
Blood creatinine increasedInvestigations2/32/35/6
LeukopeniaBlood and lymphatic system disorders2/30/31/6
NeutropeniaBlood and lymphatic system disorders2/31/32/6
ThrombocytopeniaBlood and lymphatic system disorders2/31/30/6
VomitingGastrointestinal disorders1/30/34/6
Aspartate aminotransferase increasedInvestigations0/32/31/6
White blood cell count decreasedInvestigations0/31/34/6
Decreased appetiteMetabolism and nutrition disorders2/31/33/6
NauseaGastrointestinal disorders1/30/33/6

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg AbemaciclibTotal
Mean61.3 ± 11.0663.0 ± 1.0056.0 ± 11.7059.1 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg AbemaciclibTotal
Female1157
Male2215
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg AbemaciclibTotal
American Indian or Alaska Native0000
Asian33612
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1 - 100 mg AbemaciclibCohort 2 - 150 mg AbemaciclibCohort 3 - 200 mg AbemaciclibTotal
Japan33612
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Tokyo, 104-0045, Japan
09

References and documents

Publications

  • Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13. PubMed 24919854 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Apr 2015, 15 months.

Results were first posted in Aug 2020, 5 years 4 months after primary completion.

Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 15 months is below that.

Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2013
First posted
Dec 18, 2013
StartActual
Dec 18, 2013
Primary completionActual
Apr 1, 2015
CompletionActual
Aug 21, 2019
Results first posted
Aug 24, 2020
Last update
Aug 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02014129
Responsible party
Sponsor
First posted
Dec 18, 2013
Start date
Dec 18, 2013
Primary completion
Apr 1, 2015
Completion
Aug 21, 2019
Results posted
Aug 24, 2020
Last update
Aug 24, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion